Sugi Predict

Sugi Predict / Compounds / SCHEMBL718265

SCHEMBL718265

SCHEMBL718265

NCC1Cc2ccccc2O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.49
▸ AOC2 O75106 5/20 0.49
▸ MAOA P21397 5/20 0.49
▸ MAOB P27338 5/20 0.49
▸ DAO P14920 1/20 0.49
▸ CA2 P00918 2/20 0.43
▸ PRKAB2 O43741 2/20 0.41
▸ PRKAG1 P54619 2/20 0.41
▸ PRKAA2 P54646 2/20 0.41
▸ PRKAA1 Q13131 2/20 0.41
▸ PRKAG3 Q9UGI9 2/20 0.41
▸ PRKAG2 Q9UGJ0 2/20 0.41
▸ PRKAB1 Q9Y478 2/20 0.41
▸ NISCH Q9Y2I1 1/20 0.40
▸ HTR1A P08908 1/20 0.39
▸ HTR1D P28221 1/20 0.39
▸ HTR2A P28223 2/20 0.38
▸ RET P07949 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29841223 1.00 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO
Hydrochloric Acid SCHEMBL15825664 0.98 AOC2 (0.51) HRH3AOC2MAOAMAOBDAO
SCHEMBL8026169 0.85 HRH3 (0.47) HRH3AOC2MAOAMAOBDAO
SCHEMBL8038140 0.85 HRH3 (0.47) HRH3AOC2MAOAMAOBDAO
SCHEMBL8035976 0.85 HRH3 (0.47) HRH3AOC2MAOAMAOBDAO
SCHEMBL502587 0.81 MAOA (0.40) HRH3AOC2MAOAMAOBDAO
SCHEMBL1383106 0.81 CA2 (0.59) CA2HTR1AHTR1D
SCHEMBL6084492 0.81 CA2 (0.59) CA2HTR1AHTR1D
SCHEMBL430983 0.81 CA2 (0.59) CA2HTR1AHTR1D
SCHEMBL10736602 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-7109265-A — — None — — JP disclosed
US-20240174651-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-05-30 — — US disclosed
EP-4284372-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS University of Florida Research Foundation, Incorporated (US) 2023-12-06 — — EP disclosed
EP-2816040-A1 Process for the production of CCR2 receptor antagonists and intermediates thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-12-24 — — EP disclosed
EP-1891019-B1 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS AVENTIS PHARMA INC (US) 2012-07-25 — — EP disclosed
US-8193183-B2 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists AVENTIS PHARMACEUTICALS INC. (US) 2012-06-05 — — US disclosed
US-20120053164-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-01 — — US disclosed
US-7842806-B2 Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof SANOFI-AVENTIS (FR) 2010-11-30 — — US disclosed
US-7842806-B2 Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof SANOFI-AVENTIS (FR) 2010-11-30 — — US disclosed
US-20100249102-A1 Heterotricyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) 2010-09-30 — — US disclosed
WO-2005044812-A1 DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS WYETH A CORPORATION OF THE STATE OF DELAWARE (US) 2005-05-19 — — WO disclosed
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 — — EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 — — US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 — — WO disclosed
EP-1123933-A1 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent MERCK PATENT GmbH (DE) 2001-08-16 — — EP disclosed
WO-2000076990-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2000-12-21 — — WO disclosed
US-5767132-A CENTRAL NERVOUS SYSTEM MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1998-06-16 — — US disclosed
EP-0707007-A1 Amino(thio)ether derivatives as CNS active agents MERCK PATENT GmbH (DE) 1996-04-17 — — EP disclosed
JP-H07109265-A 2,3-DIHYDROBENZOFURAN DERIVATIVE ASAHI CHEM IND CO LTD 1995-04-25 — — JP disclosed
US-3869478-A (2,3-Dihydro-2-benzofuranylmethyl)aminoguanidines STERLING DRUG INC 1975-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053164-A1 CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD CCR2, CCR1, CCR5 HRH3 45/4885AOC2 377/4885MAOA 2383/4885
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 HRH3 1607/4885AOC2 1971/4885MAOA 383/4885
US-20240174651-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS NLN, OAT, PC HRH3 4185/4885AOC2 586/4885MAOA 161/4885
US-20100249102-A1 Heterotricyclic Metalloprotease Inhibitors MMP13, MMP3, TIMP3 HRH3 3312/4885AOC2 1043/4885MAOA 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.